{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:51:10Z","timestamp":1791211870658,"version":"4.1.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, represents the leading cause of chronic liver disease globally. The increasing prevalence of the metabolic syndrome has driven a parallel rise in MASLD-related morbidity and mortality. Accurate assessment of liver fibrosis remains crucial, as liver fibrosis stage is the strongest predictor of adverse clinical outcomes. Liver biopsy, considered the gold standard for assessing liver fibrosis, is invasive and has limitations, prompting the need for reliable noninvasive alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>Serum-based biomarkers have emerged as practical tools for assessing liver fibrosis in MASLD. Conventional indices, including the Fibrosis-4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, and aspartate aminotransferase-to-platelet ratio index, are widely used for initial risk stratification due to their simplicity and accessibility. Advanced panels, such as the Enhanced Liver Fibrosis test and the PRO-C3\u2013based ADAPT score, offer improved diagnostic performance but face barriers of cost and limited availability. Novel assays, including the NIS2+\u2122 panel, demonstrate high accuracy for identifying patients with at-risk metabolic dysfunction\u2013associated steatohepatitis. Some biomarkers are currently incorporated in clinical guidelines, though many emerging biomarkers need further validation. There is promise that serum biomarkers can be effectively used to monitor long-term liver disease progression and regression in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Serum biomarkers provide an effective, noninvasive approach for evaluating liver fibrosis in MASLD. Continued refinement and validation of these assays are essential to standardize cutoff thresholds and improve clinical applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvag077","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:52:04Z","timestamp":1783687924000},"page":"1025-1038","source":"Crossref","is-referenced-by-count":0,"title":["Serum Biomarkers for the Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): An Update"],"prefix":"10.1093","volume":"72","author":[{"given":"Austin J","family":"Halupnik","sequence":"first","affiliation":[{"name":"Carver College of Medicine, University of Iowa , Iowa City, IA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio J","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Division of Gastroenterology and Hepatology, University of Iowa Health Care , Iowa City, IA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026100509520860400_hvag077-B1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2026100509520860400_hvag077-B2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"2026100509520860400_hvag077-B5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"2026100509520860400_hvag077-B6","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hep.25593","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification","volume":"56","author":"Kim","year":"2012","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100509520860400_hvag077-B11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100509520860400_hvag077-B13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD practice guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"2026100509520860400_hvag077-B15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O","year":"2024","journal-title":"J Hepatol"},{"key":"2026100509520860400_hvag077-B16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100509520860400_hvag077-B17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254939","article-title":"Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results","volume":"16","author":"Halfon","year":"2021","journal-title":"PLoS One"},{"key":"2026100509520860400_hvag077-B18","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1007\/s10620-024-08683-4","article-title":"Serial liver stiffness measurement and fibrosis-4 scores in metabolic dysfunction-associated steatotic liver disease","volume":"69","author":"Goyal","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026100509520860400_hvag077-B19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B21","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"key":"2026100509520860400_hvag077-B23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B24","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/jcm10112415","article-title":"FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"10","author":"Vali","year":"2021","journal-title":"J Clin Med"},{"key":"2026100509520860400_hvag077-B25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hep.30610","article-title":"Collagen formation assessed by N-terminal propeptide of type 3 procollagen is a heritable trait and is associated with liver fibrosis assessed by magnetic resonance elastography","volume":"70","author":"Caussy","year":"2019","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int"},{"key":"2026100509520860400_hvag077-B27","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1038\/s41598-018-30457-y","article-title":"An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis","volume":"8","author":"Luo","year":"2018","journal-title":"Sci Rep"},{"key":"2026100509520860400_hvag077-B28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J Hepatol"},{"key":"2026100509520860400_hvag077-B29","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cgh.2020.06.070","article-title":"Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis","volume":"19","author":"Are","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B30","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/gutjnl-2025-335542","article-title":"Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring","volume":"74","author":"Feng","year":"2025","journal-title":"Gut"},{"key":"2026100509520860400_hvag077-B31","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154958","article-title":"Among simple non-invasive scores, Pro-C3 and adapt best exclude advanced fibrosis in Asian patients with MAFLD","volume":"128","author":"Tang","year":"2022","journal-title":"Metabolism"},{"key":"2026100509520860400_hvag077-B32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A sequential algorithm combining adapt and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026100509520860400_hvag077-B33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the litmus project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/jcm12020650","article-title":"Cross-sectional and longitudinal performance of non-invasive tests of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"12","author":"Armandi","year":"2023","journal-title":"J Clin Med"},{"key":"2026100509520860400_hvag077-B35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12072-022-10420-w","article-title":"N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD","volume":"17","author":"Tang","year":"2023","journal-title":"Hepatol Int"},{"key":"2026100509520860400_hvag077-B36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/joim.13813","article-title":"Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD","volume":"296","author":"Hegmar","year":"2024","journal-title":"J Intern Med"},{"key":"2026100509520860400_hvag077-B37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-6-6","article-title":"Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Ratziu","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2026100509520860400_hvag077-B38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+\u2122, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"2026100509520860400_hvag077-B39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","article-title":"NIS2+(tm) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"2026100509520860400_hvag077-B40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14176148","article-title":"Is there a diagnostic miracle on the horizon? Emerging biomarkers in MASLD","volume":"14","author":"Iwaszko-Sochal","year":"2025","journal-title":"J Clin Med"},{"key":"2026100509520860400_hvag077-B42","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/cells11081312","article-title":"Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs","volume":"11","author":"Twarda-Clapa","year":"2022","journal-title":"Cells"},{"key":"2026100509520860400_hvag077-B43","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6289831","article-title":"Hepatic fat content and liver enzymes are associated with circulating free and protein-bound advanced glycation end products, which are associated with low-grade inflammation: the CODAM study","volume":"2019","author":"Bijnen","year":"2019","journal-title":"J Diabetes Res"},{"key":"2026100509520860400_hvag077-B44","doi-asserted-by":"crossref","DOI":"10.3390\/nu13103370","article-title":"Advanced glycation end-products in common non-infectious liver diseases: systematic review and meta-analysis","volume":"13","author":"Litwinowicz","year":"2021","journal-title":"Nutrients"},{"key":"2026100509520860400_hvag077-B45","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2151302","article-title":"RAGE is a potential cause of onset and progression of nonalcoholic fatty liver disease","volume":"2019","author":"Asadipooya","year":"2019","journal-title":"Int J Endocrinol"},{"key":"2026100509520860400_hvag077-B46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.metabol.2018.01.023","article-title":"Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults","volume":"83","author":"Palma-Duran","year":"2018","journal-title":"Metabolism"},{"key":"2026100509520860400_hvag077-B47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.dld.2021.02.005","article-title":"Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the atherosclerosis risk in communities study","volume":"53","author":"Laudenslager","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2026100509520860400_hvag077-B48","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Feldstein","year":"2010","journal-title":"J Lipid Res"},{"key":"2026100509520860400_hvag077-B49","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820923904","article-title":"Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"13","author":"Caussy","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"2026100509520860400_hvag077-B50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100647","article-title":"Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease","volume":"65","author":"Quehenberger","year":"2024","journal-title":"J Lipid Res"},{"key":"2026100509520860400_hvag077-B51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100127","article-title":"Clinical lipidomics: realizing the potential of lipid profiling","volume":"62","author":"Meikle","year":"2021","journal-title":"J Lipid Res"},{"key":"2026100509520860400_hvag077-B52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12876-024-03310-y","article-title":"Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study","volume":"24","author":"Elhoseeny","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"2026100509520860400_hvag077-B53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/EJE-11-0864","article-title":"Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies","volume":"166","author":"Haukeland","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2026100509520860400_hvag077-B54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/liv.12478","article-title":"Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects","volume":"35","author":"Sato","year":"2015","journal-title":"Liver Int"},{"key":"2026100509520860400_hvag077-B55","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2022","journal-title":"Gut"},{"key":"2026100509520860400_hvag077-B56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100509520860400_hvag077-B57","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"key":"2026100509520860400_hvag077-B58","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"key":"2026100509520860400_hvag077-B59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100509520860400_hvag077-B60","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"2026100509520860400_hvag077-B61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"2026100509520860400_hvag077-B62","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100509520860400_hvag077-B63","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100561","article-title":"Multi-omics profiling for health","volume":"22","author":"Babu","year":"2023","journal-title":"Mol Cell Proteomics"},{"key":"2026100509520860400_hvag077-B64","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep4.1670","article-title":"Somascan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH","volume":"5","author":"Luo","year":"2021","journal-title":"Hepatol Commun"},{"key":"2026100509520860400_hvag077-B65","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11633-024-1506-4","article-title":"Multimodal learning-based prediction for nonalcoholic fatty liver disease","volume":"22","author":"Chen","year":"2025","journal-title":"Mach Intell Res"},{"key":"2026100509520860400_hvag077-B66","article-title":"Liver fibrosis progression analyzed with AI predicts renal decline","volume":"7","author":"Sun","year":"2025","journal-title":"JHEP Rep"},{"key":"2026100509520860400_hvag077-B67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14309\/ajg.0000000000003432","article-title":"ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease","volume":"121","author":"Alkhouri","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"2026100509520860400_hvag077-B68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/HEP.0000000000000364","article-title":"Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: a development and validation study","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"},{"key":"2026100509520860400_hvag077-B69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160526","article-title":"Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease","volume":"11","author":"Xia","year":"2016","journal-title":"PLoS One"},{"key":"2026100509520860400_hvag077-B70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/hepr.13764","article-title":"Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease","volume":"52","author":"Tamaki","year":"2022","journal-title":"Hepatol Res"},{"key":"2026100509520860400_hvag077-B71","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/diseases12080180","article-title":"Practice recommendations for the management of MASLD in primary care: consensus results","volume":"12","author":"Lionis","year":"2024","journal-title":"Diseases"},{"key":"2026100509520860400_hvag077-B72","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"A global survey of physicians knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/10\/1025\/68754561\/hvag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/10\/1025\/68754561\/hvag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:52:22Z","timestamp":1791208342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/72\/10\/1025\/8731901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvag077","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,10]]}}}